Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Partners Fund Ron Baron | “We initiated a position in Edwards Lifesciences Corporation, a leading manufacturer of heart valve replacement and repair products. Edwards has dominant market share in transcatheter aortic valve replacement (TAVR), a minimally invasive procedure used to treat aortic stenosis, a disease that obstructs the flow of blood throughout the body and strains the heart. If left untreated, the condition can lead to death. Edwards' position in this market is supported by a robust body of positive clinical evidence and widespread physician familiarity with Edwards' product and workflow. We believe that today's $7 billion market for TAVR can grow to more than $10 billion as approved indications expand to allow TAVR to cover a broader patient population. In addition, Edwards' competitor Boston Scientific recently exited the TAVR market, and another competitor, Medtronic, released poor data about its product that we expect will drive additional market share to Edwards. Furthermore, recent policies implemented by Medicare should expand the number of medical centers that can perform TAVR procedures. Edwards also manufactures products used to treat the heart's mitral and tricuspid valves (TMTT). When these valves are dysfunctional, the heart can be forced to work harder, becoming strained and possibly leading to death. Edwards is in the unique position of offering patients options for both valve repair and replacement. The company has devoted more than a decade of research to develop its TMTT portfolio. Addressing TMTT issues is structurally much more complex than TAVR, and the barrier to developing effective solutions is extremely high. We believe that today's $1.5 billion TMTT market can grow to as much as $8 billion over time. With a combined addressable market of nearly $20 billion, we believe Edwards has meaningful opportunity to compound growth. The company also has an attractive and improving margin structure, with 78% gross margins and 27% operating margins. With a more stable competitive landscape in TAVR and large greenfield opportunity in TMTT, we believe Edwards can compound its revenues at low double digit rates and its earnings per share in the mid-teens for an extended period.” | NEUTRAL | Q2 2026 Aug 12, 2026 | View Pitch |
Aristotle Value Equity Fund Howard Gleicher | “Headquartered in Irvine, California, Edwards Lifesciences (Edwards) is a global leader in structural heart disease therapies, developing and commercializing medical devices used to treat advanced cardiovascular conditions. The company is best known for its leadership in transcatheter aortic valve replacement (TAVR), a minimally invasive procedure that allows physicians to replace diseased heart valves without open-heart surgery. By reducing the invasiveness, recovery time and risk associated with traditional surgical valve replacement, TAVR has significantly expanded the number of patients eligible for treatment and accelerated adoption across the structural heart market. We have followed Edwards for many years as both a leading structural heart company and a competitor to Medtronic's CoreValve platform. Over the last decade, Edwards effectively bet the company on TAVR technology and successfully established its Sapien platform as one of the leading transcatheter heart valve systems globally while maintaining a meaningful presence in surgical aortic valve replacement (SAVR). Today, TAVR represents the core of Edwards' business and is supported by a large global installed base, extensive physician training and extensive long-term clinical evidence, reinforcing its position as a standard of care for aortic stenosis. Beyond TAVR, Edwards is expanding into transcatheter mitral and tricuspid therapies (TMTT), which represent a significantly larger but more underpenetrated market opportunity. The company is also investing in adjacent cardiovascular technologies, supported by continued investment in research and development, targeted acquisitions and substantial FREE cash flow generation. While the TAVR market is more developed, we believe both the continued expansion of this franchise and the scaling contribution from newer mitral and tricuspid therapies are not fully reflected in the current stock price. As these businesses continue to scale and adoption broadens, we expect continued improvement in operating performance and FREE cash flow generation over our investment horizon.” | NEUTRAL | Q2 2026 Aug 10, 2026 | View Pitch |
Castlebay Investments David F. Ridland | “Edwards Lifesciences is a genuinely high-quality business. Its clinical moat in transcatheter heart valves is real and its procedure data is unrivalled. Its management has demonstrated sustained execu” | BULL | Q1 2026 Apr 13, 2026 | View Pitch |
Wedgewood Partners David A. Rolfe, Michael X. Quigley, Christopher T. Jersan | “Edwards Lifesciences also contributed to performance during the quarter. The Company presented favorable seven-year data for its transcatheter aortic valves, while competitive valves exited several key markets. Edwards can drive double-digit earnings growth over the next few years as its long-term data evolves standards of care. Minimally invasive alternatives are increasingly preferred over open-heart surgery. This positions Edwards for sustained procedure growth and share gains. BSD Analysis: Edwards is a structural winner in heart valve therapy, a category with aging-driven demand and strong clinical moats. The TAVR franchise is mature, but procedure volumes still have runway as adoption expands globally. Competitive pressure is real, yet physician preference and clinical outcomes keep Edwards relevant. The pipeline in structural heart adds growth optionality beyond the core valve business. Hospitals don't switch vendors lightly in life-or-death procedures, which supports stickiness. Investors punish any growth wobble because the stock has worn a premium for years. If new products scale, multiple expansion can return quickly. This is high-quality medtech with a pipeline-shaped catalyst map.” | BULL | Q4 2025 Jan 8, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
